NRIX Projected Dividend Yield
Nurix Therapeutics Inc ( NASDAQ : NRIX )Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications. 20 YEAR PERFORMANCE RESULTS |
NRIX Dividend History Detail NRIX Dividend News NRIX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |